Coya Therapeutics, Inc. (COYA)

Coya Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	9.55	6	-	-	-
Cost of Revenue	11.54	5.5	4.41	-	-
Gross Profit	-1.98	0.5	-4.41	-	-
Selling, General & Admin	9.13	7.83	4.85	2.31	0.67
Research & Development	-	-	-	2.54	0.04
Operating Expenses	9.15	7.86	4.87	4.87	0.7
Operating Income	-11.14	-7.36	-9.29	-4.87	-0.7
Interest Expense	-	-	-	-	-0.06
Other Non Operating Income (Expenses)	1.38	0.64	-2.43	-0.02	0
EBT Excluding Unusual Items	-9.76	-6.72	-11.72	-4.89	-0.76
Pretax Income	-9.98	-7.26	-12.24	-4.89	-1.1
Income Tax Expense	0.72	0.72	-	-	-
Net Income	-10.7	-7.99	-12.24	-4.89	-1.1
Net Income to Common	-10.7	-7.99	-12.24	-4.89	-1.1
Shares Outstanding (Basic)	14	10	3	3	2
Shares Outstanding (Diluted)	14	10	3	3	2
Shares Change (YoY)	72.72%	292.40%	0.01%	40.88%	-
EPS (Basic)	-0.77	-0.79	-4.73	-1.89	-0.60
EPS (Diluted)	-0.77	-0.79	-4.73	-1.89	-0.60
Free Cash Flow	-10.12	-11.19	-7.24	-4.04	-0.59
Free Cash Flow Per Share	-0.73	-1.10	-2.79	-1.56	-0.32
Gross Margin	-20.76%	8.34%	-	-	-
Operating Margin	-116.56%	-122.62%	-	-	-
Profit Margin	-111.98%	-133.08%	-	-	-
Free Cash Flow Margin	-105.92%	-186.41%	-	-	-
EBITDA	-11.11	-7.33	-9.26	-4.85	-
EBITDA Margin	-116.27%	-122.17%	-	-	-
D&A For EBITDA	0.03	0.03	0.03	0.02	-
EBIT	-11.14	-7.36	-9.29	-4.87	-0.7
EBIT Margin	-116.56%	-122.62%	-	-	-

Source: S&P Capital IQ. Standard template. Financial Sources.